PT - JOURNAL ARTICLE AU - Chen, Yu AU - Liu, Sihan AU - Ren, Zongyao AU - Wang, Feiran AU - Jiang, Yi AU - Dai, Rujia AU - Duan, Fangyuan AU - Han, Cong AU - Ning, Zhilin AU - Xia, Yan AU - Li, Miao AU - Yuan, Kai AU - Qiu, Wenying AU - Yan, Xiao-Xin AU - Dai, Jiapei AU - Kopp, Richard F. AU - Huang, Jufang AU - Xu, Shuhua AU - Tang, Beisha AU - Gamazon, Eric R. AU - Bigdeli, Tim AU - Gershon, Elliot AU - Huang, Hailiang AU - Ma, Chao AU - Liu, Chunyu AU - Chen, Chao TI - Brain eQTLs of European, African American, and Asian ancestry improve interpretation of schizophrenia GWAS AID - 10.1101/2024.02.13.24301833 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.13.24301833 4099 - http://medrxiv.org/content/early/2024/02/16/2024.02.13.24301833.short 4100 - http://medrxiv.org/content/early/2024/02/16/2024.02.13.24301833.full AB - Research on brain expression quantitative trait loci (eQTLs) has illuminated the genetic underpinnings of schizophrenia (SCZ). Yet, the majority of these studies have been centered on European populations, leading to a constrained understanding of population diversities and disease risks. To address this gap, we examined genotype and RNA-seq data from African Americans (AA, n=158), Europeans (EUR, n=408), and East Asians (EAS, n=217). When comparing eQTLs between EUR and non-EUR populations, we observed concordant patterns of genetic regulatory effect, particularly in terms of the effect sizes of the eQTLs. However, 343,737 cis-eQTLs (representing ∼17% of all eQTLs pairs) linked to 1,276 genes (about 10% of all eGenes) and 198,769 SNPs (approximately 16% of all eSNPs) were identified only in the non-EUR populations. Over 90% of observed population differences in eQTLs could be traced back to differences in allele frequency. Furthermore, 35% of these eQTLs were notably rare (MAF < 0.05) in the EUR population. Integrating brain eQTLs with SCZ signals from diverse populations, we observed a higher disease heritability enrichment of brain eQTLs in matched populations compared to mismatched ones. Prioritization analysis identified seven new risk genes (SFXN2, RP11-282018.3, CYP17A1, VPS37B, DENR, FTCDNL1, and NT5DC2), and three potential novel regulatory variants in known risk genes (CNNM2, C12orf65, and MPHOSPH9) that were missed in the EUR dataset. Our findings underscore that increasing genetic ancestral diversity is more efficient for power improvement than merely increasing the sample size within single-ancestry eQTLs datasets. Such a strategy will not only improve our understanding of the biological underpinnings of population structures but also pave the way for the identification of novel risk genes in SCZ.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by National Natural Science Foundation of China (Grants Nos. 82022024, 31571312, and 91632116), the National Key R&D Project of China (Grants No. 2016YFC1306000), The Science and Technology Innovation Program of Hunan Province (2021RC4018, 2021RC5027), and NIH grant R01MH126459-01A1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Central South University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes